Jefferies Bullish on GSK, Citing Growth Pipeline and Efficiency Prospects

Core Viewpoint - GSK plc is recognized as a strong investment opportunity, particularly noted for its growth pipeline and efficiency prospects, with a recent Buy rating from Jefferies and a price target of 2,000 GBp [3][4]. Financial Performance - GSK reported total sales of £8.5 billion for Q3 2025, reflecting a 5% increase compared to the same quarter last year [4]. - The company generated £2.5 billion from operations and had a free cash flow of £1.2 billion, which supported a dividend payout of £1.9 billion to shareholders [4]. - GSK offers a dividend yield of 3.56% as of October 29 [4]. Market Position - GSK is included among the 11 Best FTSE Dividend Stocks to Buy Right Now, highlighting its strong position in the market [1]. - The company operates in multiple therapeutic fields, including vaccines, respiratory, and oncology, indicating a diversified portfolio [2]. Analyst Insights - Jefferies initiated coverage on GSK with a Buy rating, emphasizing the potential for significant upside due to a 30% discount on the stock [3]. - The new CEO is expected to implement an efficiency program, with early signs of progress in the company's pipeline and potential for further business development [3].